Novavax | NVAX - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Adma Biologics USD 390.32M 86.99M 2026-03
Agenus USD -221.22M 49.89M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
Cassava Sciences USD 68.14M 6.26M 2026-03
Geron USD 229.11M 3.24M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
MannKind USD -59.2M 8.17M 2026-03
Merck USD 45.88B 6.73B 2026-03
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 7.41B 1.24B 2026-03
Novartis USD 46.13B 1.8B 2025-12
Novavax USD -144.76M 17.01M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Sanofi EUR 72.81B 1.1B 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
TG Therapeutics USD 583.13M 64.89M 2026-03